Purpose The goal of this study was to generate and characterize the Fab fragment of TRC105, a monoclonal antibody that binds with high affinity to human and murine CD105 (i.e., endoglin), and investigate its potential for PET imaging of tumor angiogenesis in a small-animal model after 61/64 Cu labeling. Methods TRC105-Fab was generated by enzymatic papain digestion. The integrity and CD105 binding affinity of TRC105-Fab was evaluated before NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) conjugation and 61/64 Cu labeling. Serial PET imaging and biodistribution studies were carried out in the syngeneic 4T1 murine breast cancer model to quantify tumor targeting efficiency and normal organ distribution of 61/64 Cu-NOTA-TRC105-Fab. Blocking studies with unlabeled TRC105 were performed to confirm CD105 specificity of the tracer in vivo. Immunofluorescence staining was also conducted to correlate tracer uptake in the tumor and normal tissues with CD105 expression.
Introduction
The growth and metastasis of most solid tumors depends on angiogenesis, without which they cannot grow beyond a few millimeters in size [1] . During the last decade, many studies have been published on tumor angiogenesis (especially with the use of molecular imaging techniques), making it an extremely dynamic research area [2] [3] [4] . The most widely studied angiogenesis-related targets include integrin α v β 3 , vascular endothelial growth factor receptors (VEGFRs), and CD105 (i.e., endoglin) [3] [4] [5] [6] [7] [8] [9] [10] . Several tracers targeting these receptors are already under clinical investigation [3, 7, 9] .
Primarily overexpressed on proliferating endothelial cells, CD105 has recently emerged as a promising candidate for tumor vascular targeting [8, 11, 12] . CD105 immunohistochemistry is now the accepted standard approach for identifying actively proliferating tumor vessels. High CD105 microvessel density (MVD) correlates with poor prognosis in multiple tumor types, including breast cancer [11] .
To date, PET imaging of CD105 has not been investigated in the clinic. Future translation of the optimized PET tracer(s) for CD105 imaging (i.e., noninvasive full-body MVD measurement) can play multiple roles in improving the management of cancer patients. We recently reported the first PET imaging of CD105 expression in a mouse model of breast cancer using a 64 Cu-labeled chimeric monoclonal antibody TRC105, which has high avidity for both human and murine CD105 [13] . A multicenter phase 1 first-in-human dose-escalation trial of TRC105 has been completed and multiple phase 2 trials are underway in a number of solid tumor types [14] .
One major limitation of imaging/diagnostic agents based on intact antibodies is the prolonged circulation half-life [15] . Typically, tumor uptake does not reach a peak until a few days after tracer injection. This has motivated the development of antibody fragment-based imaging probes that exhibit good targeting efficacy and rapid blood clearance to allow potentially for same-day imaging in the clinic [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . IgG antibodies are composed of Fc and Fab fragments, with the latter containing the antigen binding sites. For immunoPET applications, the use of small antibody fragment such as Fab, which exhibits rapid blood clearance, and positron emitters with suitable half-lives such as 64 Cu (t 1/2 12.7 h) or 61 Cu (t 1/2 3.4 h) may be advantageous. The goal of this study was to investigate the in vitro and in vivo characteristics of 64 Cu-labeled TRC105-Fab for PET imaging of tumor angiogenesis in a 4T1 murine breast cancer model. Since radiolabeled Fab is expected to have rapid blood clearance and tumor uptake, we hypothesized that 61 Cu labeling may also provide sufficient tumor contrast to allow visualization at early time points. The rationale for using 61 Cu as the PET isotope is that it has a higher β + branching ratio (62 % vs. 17 %) and shorter decay half-life (3.4 h vs. 12.7 h) than 64 Cu, which is expected to provide a stronger PET signal and lower radiation dosimetry to normal organs than the corresponding 64 Cu-based PET tracer. Generation and characterization of TRC105-Fab TRC105 (2 mg/mL) was digested out in a reaction buffer (20 mM sodium phosphate monobasic, 10 mM disodium ethylenediaminetetraacetic acid (EDTA), and 80 mM cysteine.HCl) for 4 h at 37°C, with immobilized papain/TRC105 at a weight ratio of 1:40 [16] . Afterwards, the reaction mixture was centrifuged at 5000×g for 1 min to remove the immobilized papain. The supernatant was purified by size exclusion column chromatography on a Sephadex G-75 column to yield TRC105-Fab, using phosphate-buffered saline (PBS) as the mobile phase. The concentration of TRC105-Fab was determined from UV absorbance at 280 nm using an extinction coefficient of 1.4 mL/mg/cm [26] . The purity of TRC105-Fab was evaluated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; 5 % stacking gel and 8 % resolving gel; nonreducing conditions) using Coomassie brilliant blue R-250 staining. The molecular weight of TRC105-Fab was determined by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry, which served as a reference for the TRC105-Fab band in SDS-PAGE. In addition, high-performance liquid chromatography (HPLC) analysis was conducted to evaluate the purity of TRC105-Fab and TRC105 in a Dionex Ultimate 3000 system using a ProPac WCX-10 column (eluent A: 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 1 mM EDTA, 40 mM NaCl, pH5.5; eluent B: 20 mM MES, 1 mM EDTA, 250 mM NaCl, pH5.5). The NaCl gradient used was 3.75 mM/min with a flow rate of 1 mL/min. Absorbance at 280 nm was used for protein detection. Cu labeling NOTA conjugation was carried out at pH9.0, with the reaction ratio of p-SCN-Bn-NOTA to TRC105-Fab being 10:1. NOTA-TRC105-Fab was purified using PD-10 columns with PBS as the mobile phase. A similar reaction and purification procedure was adopted for conjugation of FITC (for flow cytometry analysis) or AlexaFluor350 NHS ester (for histology applications) onto TRC105-Fab, except that the reaction ratio of FITC or AlexaFluor350 NHS ester to TRC105-Fab was 3:1 to limit the number of dyes per TRC105-Fab and avoid self-quenching of the fluorescence signal.
Materials and methods

Chemicals
The two PET isotopes were produced using Cu-NOTA-TRC105-Fab was purified using PD-10 columns with PBS as the mobile phase. The radioactive fractions containing 61/64 Cu-NOTA-TRC105-Fab were collected and passed through a 0.2-μm syringe filter before in vivo studies.
Flow cytometry
The CD105 binding affinity/specificity of TRC105-Fab was evaluated by fluorescence-activated cell sorting (FACS) analysis in two cell lines: human umbilical vein endothelial cells (HUVECs, high CD105 expression [13, 27] ) and MCF-7 human breast cancer cells (CD105-negative [13, 28] ). Cells were harvested and suspended in cold PBS (pH 7.4) with 2 % bovine serum albumin at a concentration of 5×10 6 cells/mL, and were incubated with various concentrations of FITC-TRC105-Fab (5, 25, or 100 nM) for 30 min at room temperature, washed and centrifuged at 1,000 rpm for 5 min. Afterwards, the cells were analyzed by FACS using a BD FACSCalibur four-color analysis cytometer (Becton-Dickinson, San Jose, CA) and FlowJo analysis software (Tree Star, Inc., Ashland, OR).
PET imaging and biodistribution studies
The 4T1 murine breast cancer model was generated as previously described [13, 29] . PET and PET/CT scans of tumor-bearing female BALB/c mice (6-8 weeks old, tumor diameter 5-8 mm) were performed using an Inveon micro-PET/microCT rodent model scanner (Siemens Medical Solutions USA, Inc.). Each mouse was intravenously injected with 5-10 MBq of 61/64 Cu-NOTA-TRC105-Fab and 5-or 10-min static PET scans were performed at various time points postinjection (p.i.). The images were reconstructed using a maximum a posteriori algorithm, with no attenuation or scatter correction. Region-of-interest (ROI) analysis of each PET scan was performed using vendor software (Inveon Research Workplace, IRW) on decay-corrected wholebody images, as described previously [30, 31] , to calculate the percentage injected dose per gram of tissue (%ID/g) values for the 4T1 tumor and several major organs.
Blocking studies were carried out to evaluate CD105 specificity of 64 Cu-NOTA-TRC105-Fab in vivo, in which a group of four mice were each injected with 2 mg of TRC105 within 1 h before 64 Cu-NOTA-TRC105-Fab administration. After the last PET scans at 24 h p.i., mice were killed and the blood, 4T1 tumor, and major organs/tissues were collected and wetweighed. The radioactivity in the tissue was measured using a Cobra II gamma-counter (Perkin-Elmer) and presented as %ID/g. The 4T1 tumor, liver, kidney (i.e., tissues with significant uptake of 61/64 Cu-NOTA-TRC105-Fab), and muscle were also frozen and sectioned for histological analysis.
Histology
Frozen tissue slices of 7 μm thickness were fixed with cold acetone for 10 min and dried in the air for 30 min. After rinsing with PBS and blocking with 10 % donkey serum for 30 min at room temperature, the slices were incubated with TRC105 (2 μg/mL) for 1 h at 4°C and visualized using AlexaFluor488-labeled goat anti-human IgG. After washing with PBS, the tissue slices were also stained for endothelial marker CD31 as described previously [13] . Subsequently, the slices were incubated with AlexaFluor350-TRC105-Fab (2 μg/mL) for 30 min. Hematoxylin staining was also carried out to demarcate the cell nuclei in the tissue slices. After washing with PBS, all images were acquired with a Nikon Eclipse Ti microscope.
Statistical analysis
Quantitative data are presented as means ± SD. Means were compared using the Mann-Whitney U test. P values <0.05 were considered statistically significant.
Results
Generation and characterization of TRC105-Fab
Following papain digestion, TRC105-Fab was separated from other components in the reaction mixture using a Sephadex G-75 column (fractionation range 3,000-70,000 Da). The elution profile is shown in Fig. 1a and only the single fraction with the highest TRC105-Fab concentration was used for further studies. SDS-PAGE showed the disappearance of the TRC105 band expected at about 148 kDa and the appearance of pure TRC105-Fab (Fig. 1b) , which was confirmed by HPLC analysis (Fig. 1c) . Taken together, these findings indicate complete digestion of TRC105 after papain treatment to yield high purity TRC105-Fab for further bioconjugation and investigation. Mass spectrometry indicated that TRC105 has a molecular weight of about 148 kDa and TRC105-Fab has a molecular weight of about 47.5 kDa (Fig. 1d) , which was consistent with the molecular weight predicted by amino acid analysis.
Flow cytometry
As indicated in Fig. 2 , treatment with FITC-TRC105-Fab significantly enhanced the mean fluorescence intensity of HUVECs (about 12-fold higher than the unstained cells at 25 nM), whereas treatment with a "blocking" dose of TRC105 (1 μM) reduced the cell fluorescence by about 10-fold. These results demonstrate that FITC-TRC105-Fab specifically binds to CD105 on the HUVECs. Meanwhile, the fluorescence signal on CD105-negative MCF-7 cells was minimal for all groups even when treated with FITC-TRC105-Fab at a much higher concentration (100 nM), indicating low nonspecific binding of FITC-TRC105-Fab in cell culture. Overall, the FACS studies demonstrated that FITC-TRC105-Fab exhibits strong and specific binding to CD105 on cells with minimal nonspecific binding, indicating that papain digestion did not Cu labeling [32] [33] [34] .
61/64
Cu labeling, including purification using PD-10 columns, took 60±10 min (n=8). The decay-corrected radiochemical yield was 50.2±10.4 %, based on 20 μg of NOTA-TRC105-Fab per 37 MBq of 64 Cu, with radiochemical purity of >95 %. The specific activity was about 44 GBq/μmol, assuming complete recovery of NOTA-TRC105-Fab after size exclusion column chromatography.
The coronal PET slices that encompassed 4T1 tumors are shown in Fig. 3a and representative PET/CT fused images of a mouse at 5 h p.i. of 64 Cu-NOTA-TRC105-Fab is shown in Fig. 3b . 61 Cu-NOTA-TRC105-Fab exhibited a similar in vivo distribution pattern to 64 Cu-NOTA-TRC105-Fab at early time points (Fig. 3c) . Quantitative data obtained from ROI analysis of the PET results are shown in Fig. 4 .
Due to its much smaller size compared to the parent antibody TRC105 (47.5 kDa vs. 148 kDa), 64 Cu-NOTA-TRC105-Fab was cleared through both the hepatobiliary and renal pathways. Cu-NOTA-TRC105, which had blood radioactivity levels of 16.2±1.9, 10.7±2.0, and 8.3±0.9 %ID/g at 4, 24, and 48 h p.i., respectively (n =3) [34] . Importantly, 64 Cu-NOTA-TRC105-Fab accumulated rapidly in the tumor and was clearly visible as early as 0.5 h p.i., peaked at 5 h p.i., and remained prominent over time (3.6±0.4, 4.2±0.5, 4.9±0.3, 4.4±0.7, and 4.6±0.8 %ID/g at 0.5, 2, 5, 16, and 24 h p.i., respectively; n=4; Figs. 3a and 4a) . Because of the rapid blood clearance and tumor uptake of radiolabeled TRC105-Fab, 61 Cu-NOTA-TRC105-Fab was also able to provide tumor contrast at the time points of 3 and 8 h p.i. (Fig. 3c) .
Administering a blocking dose of TRC105 significantly reduced the tumor uptake of Fig. 4a, b) . Figure 4c summarizes the 4T1 tumor uptake of the tracer in both groups. The differences in tumor %ID/g values were statistically significant (P<0.05; n=4) at all time points examined except 24 h p.i., when most of the tracer has already been cleared from the mice. After the last PET scans at 24 h p.i., biodistribution studies confirmed that the quantitation of tracer uptake based on PET imaging accurately reflected the radioactivity distribution in tumor-bearing mice, as similar %ID/g values were calculated from the PET and the biodistribution results (Fig. 5) . More importantly, the 4T1 tumor uptake of 64 Cu-NOTA-TRC105-Fab was higher than the uptake in all major organs except the liver and kidneys (which are responsible for tracer clearance), and thus provided good tumor contrast.
The peak uptake of 64 Cu-NOTA-TRC105-Fab in the 4T1 tumor (4.9±0.3 %ID/g at 5 h p.i.; n=4) was lower than that of 64 Cu-NOTA-TRC105 (13.0±1.2 %ID/g at 48 h p.i.; n=3), which would be expected for radiolabeled antibody fragments [35] . However, the tumor-to-blood ratios were significantly better at early time points for Cu may increase the PET signal intensity (due to the higher β + branching ratio) and reduce the radiation dosimetry to normal organs (attributed to the shorter decay half-life). 
Histology
Immunofluorescence CD105/CD31 costaining of various tissues revealed that CD105 expression in the 4T1 tumor was primarily on the tumor vasculature, as evidenced by excellent colocalization of CD105 and CD31 staining and virtually undetectable signal on the 4T1 tumor cells (Fig. 6) . The staining with AlexaFluor350-TRC105-Fab gave excellent overlay with both CD105 and CD31 staining in the 4T1 tumor, which confirmed that TRC105-Fab and 61/64 Cu-NOTA-TRC105-Fab bind with good affinity and specificity to CD105 on the tumor vasculature.
CD105 staining of mouse liver and muscle gave very low intensity signals, indicating that these tissues do not have significant CD105 expression. Thus, uptake of 61/64 Cu-NOTA-TRC105-Fab in the liver could be largely attributed to nonspecific hepatic clearance instead of CD105-mediated binding. The appreciable CD105 expression in the kidneys may be partially responsible for high tracer uptake in the kidneys, in addition to that attributed to renal clearance. This phenomenon may also explain the significantly lower tracer uptake in the kidneys after administration of a preinjected blocking dose of TRC105, as part of 64 Cu-NOTA-TRC105-Fab uptake in the kidneys is CD105-specific.
Discussion
Tumor cells rely on the formation of new blood vessels for adequate nutrition during tumor growth. Tremendous effort has been devoted over the last two decades to discovering specific markers for newly formed tumor vessels and a number of targets have been investigated for noninvasive imaging of tumor angiogenesis [2] [3] [4] . CD105 has several advantages over the other targets, including high levels of expression in a wide variety of solid malignancies, independence from its expression on neoplastic cells (including the 4T1 tumor model employed here), lack of tumor histotype specificity, and immediate accessibility of malignant lesions through the bloodstream [12, 36] . Our group has previously demonstrated the ability of TRC105 with various radiolabels for the noninvasive PET imaging of CD105 expression during tumor angiogenesis in several preclinical tumor models [13, 27, 29, 31, 34, 37] . Delayed tracer uptake in the tumor tissue and slow clearance from the circulation are two major hurdles faced by immunoPET with radiolabeled intact antibodies, which could be improved through the use of antibody fragments [15] . For imaging applications, achieving tumor contrast faster is highly desirable [38] [39] [40] . Therefore, the use of Fab or other engineered antibody fragments instead of intact antibodies as the targeting ligands may be advantageous [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Furthermore, intact antibodies may trigger immune responses that are not desirable for imaging applications.
TRC105-
TRC105 is a chimeric IgG1 monoclonal antibody composed of four peptide chains (two heavy and two light chains), with a molecular weight of about 148 kDa. Being a much smaller molecule of about 47.5 kDa, TRC105-Fab is expected to have a faster clearance from blood and an improved penetration into solid tumors. The caveat for using an antibody fragment such as Fab is the lower tumor uptake of the tracer than of the similarly labeled intact antibody, which was observed in this study. This phenomenon may be partially attributed to the decreased internalization efficiency of a Fab fragment because of the lack of Fc, which can play an important role in antibody internalization. On the other hand, the lack of Fc may eliminate nonspecific binding between Fc and its receptors on various types of cells (e.g., macrophages, dendritic cells, neutrophils, natural killer cells, B cells etc.) and improve the tumor-to-normal tissue ratio [41] . The decreased uptake of 64 Cu-NOTA-TRC105-Fab in the mouse spleen compared to 64 Cu-NOTA-TRC105 may be partially attributed to the lack of Fc-mediated binding. The uptake of 64 Cu-NOTA-TRC105-Fab in mouse kidneys may be unique to mouse tissue as antibodies to human CD105 have been reported to bind specifically to kidney tumors but not normal renal parenchyma [42] .
The Cu may be preferred over the more widely available 64 Cu for immunoPET with small antibody fragments. Several other PET isotopes also exhibit desirable characteristics for antibody fragment-based imaging (e.g., 45 Ti and 44 Sc, both have half-lives similar to that of 61 Cu, high β + branching ratios, and low β + energies), and warrant future evaluation. 4T1 breast cancer is a highly vascularized tumor model that grows rapidly upon implantation and provides a sufficient number of vessels for in vivo imaging of angiogenesis (MVD of the 4T1 tumor was 205±29 vessels/mm 2 based on CD105 histology; n=8). In addition, CD105-targeted antiangiogenic therapy has been shown to be effective in this tumor model [44] . One limitation of this model is that the tumor vasculature is of murine origin. TRC105 is known to have a significantly higher affinity to human CD105 than its murine homolog [45] . Therefore, it is possible that the tracer may perform better in future clinical applications than was observed in experimental animal tumor models. With demonstrated affinity/specificity for CD105 in this study, radiolabeled TRC105-Fab has the potential to serve as a promising imaging/diagnostic agent for same-day immunoPET imaging in cancer patients in the future.
Conclusion
We report the development, characterization, and in vivo investigation of a 61/64 Cu-labeled Fab fragment of TRC105 for PET imaging of tumor angiogenesis in a murine breast cancer model. Rapid, prominent, and target-specific uptake in the 4T1 tumor was observed for 61/64 Cu-NOTA-TRC105-Fab. Further optimization and clinical translation of radiolabeled TRC105-Fab for PET imaging of tumor angiogenesis may lead to improvements in the management of cancer patients (e.g., patient stratification and treatment monitoring), as well as facilitate the development of novel antiangiogenic drugs.
